Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Aug 24, 2023

Beyfortus™ (nirsevimab-alip) recommended for routine use to protect infants against RSV disease in CDC Morbidity and Mortality Weekly Report

The recommendation helps to ensure all infants have the opportunity to be protected from RSV disease ahead of the next winter virus season
Aug 3, 2023

U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
Jul 25, 2023

Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact
Jul 17, 2023

FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
Jun 25, 2023

ALTUVIIIO™ late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing
Jun 8, 2023

FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants
Jun 2, 2023

New data from Sanofi’s diverse, differentiated oncology pipeline and portfolio to be presented at ASCO 2023
May 21, 2023

Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
May 18, 2023

Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi
May 5, 2023

New late-breaking data at ATS 2023 demonstrate significant advancements across Dupixent® and broader respiratory pipeline

17 abstracts showcase new data for Dupixent, itepekimab and anti-IL-13/TSLP NANOBODY® molecule in COPD and asthma

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.